Targeted therapy for hepatocellular carcinoma

Area of Science:

• Oncology
• Hepatology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent global malignancy with well-defined risk factors.
• Despite advances in early detection, patient survival for HCC has stagnated over the past 30 years.
• Limited therapeutic options exist for the majority of patients presenting with advanced or multifocal HCC.

Purpose of the Study:

• To review the mechanisms of targeted therapies in HCC treatment.
• To discuss clinical studies evaluating targeted therapies for HCC.
• To provide perspectives on future developments in HCC therapy.

Main Methods:

• Literature review of targeted therapies in hepatocellular carcinoma.
• Analysis of clinical trial data for HCC targeted treatments.
• Discussion of molecular mechanisms underlying targeted therapy efficacy.

Main Results:

• Targeted therapies, including monoclonal antibodies and kinase inhibitors, show efficacy in various tumors.
• Sorafenib, a multitargeted kinase inhibitor, significantly prolonged survival in advanced HCC patients in 2007.
• Current therapeutic strategies are insufficient for over 80% of HCC patients diagnosed with advanced disease or comorbidities.

Conclusions:

• Targeted therapies represent a significant advancement in managing advanced HCC.
• Further research into novel targeted agents and treatment combinations is crucial for improving HCC patient outcomes.
• The development of targeted therapies offers new hope for patients with limited treatment options.